Daiichi Sankyo and AstraZeneca have secured European Commission approval for Enhertu, or trastuzumab deruxtecan, as monotherapy for adults with unresectable or metastatic HER2-positive IHC 3+ solid tumors after prior treatment and when no satisfactory options remain. The decision makes Enhertu the first HER2-directed therapy and antibody drug conjugate in the European Union with a tumor-agnostic indication, extending the medicine beyond its established breast, gastric and lung cancer settings.
Why this approval changes the treatment framework more than it expands a single label
The importance of the approval lies in how patients can be selected, rather than simply in the number of cancers added to the Enhertu label. Treatment decisions have traditionally been organized around the organ in which a cancer originated, with separate development programmes, clinical guidelines and reimbursement pathways for breast, lung, colorectal, ovarian and other tumors. A tumor-agnostic indication allows a shared biological feature, in this case strong HER2 protein expression, to become the central treatment criterion across multiple cancer types.
That shift supports the broader movement toward precision oncology, in which molecular and protein characteristics increasingly influence treatment after standard options have been exhausted. It may be particularly relevant for patients with uncommon cancers or rare biomarker-defined subgroups that are too small to support conventional phase 3 development programmes. A broad label can give oncologists a regulatory route to use Enhertu without waiting for a separate approval in every individual tumor type.
The scope is nevertheless narrower than the phrase “tumor agnostic” may initially suggest. Eligibility is limited to tumors classified as HER2-positive with an immunohistochemistry score of 3+, rather than the broader HER2-low or HER2-expressing populations studied in some breast cancer settings. Patients must also have received previous treatment and lack satisfactory alternatives, positioning Enhertu as a later-line option rather than a universal early treatment for HER2-expressing cancers.
The approval therefore creates an additional treatment route, not a replacement for tumor-specific standards. Existing chemotherapy, immunotherapy, targeted therapy and surgery pathways will continue to determine when a patient has reached the point at which the new indication becomes relevant. Its immediate clinical value will be greatest where strong HER2 expression is present and established treatment options are limited or have already failed.
How convincing is the phase 2 evidence supporting a pan-tumor regulatory decision?
The European decision was supported by HER2-positive patient subgroups from three phase 2 studies, DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. Across the studies, objective responses were observed in roughly half of treated patients, an outcome that is clinically notable in heavily pretreated populations with limited remaining options.
In the HER2-positive subgroup of DESTINY-PanTumor02, the confirmed objective response rate was 52.3%, with a median response duration of 21.1 months. The study covered several malignancies, including biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers, as well as other tumors. The durability reported in this broader basket trial indicates that HER2 overexpression can function as a meaningful treatment target outside the cancers in which HER2 therapy is already well established.
The results were less uniform across the supporting datasets. DESTINY-Lung01 produced a confirmed response rate of 52.9% among 17 patients with HER2-positive non-small cell lung cancer, but the median response duration was 6.9 months. DESTINY-CRC02 reported a response rate of 46.9% among 64 patients with HER2-positive colorectal cancer, with a median response duration of 5.5 months.
These differences matter because a tumor-agnostic label does not mean that every cancer is equally dependent on HER2 or equally sensitive to the same antibody drug conjugate. Tumor biology, prior treatment exposure, resistance pathways, payload sensitivity and the surrounding tumor environment may influence both the probability and duration of benefit. An aggregate response rate can demonstrate activity across cancers while still concealing important variation between individual tumor types.
The evidence also comes with limitations. The approved population was drawn from relatively small subgroups, and the studies did not provide randomized comparisons against an active standard of care for the pan-tumor indication. Objective response rate and duration of response are useful endpoints in late-line oncology, especially where treatment choices are poor, but they do not independently establish an overall survival advantage or determine the best treatment sequence.
The approval consequently reflects a regulatory balance between meaningful antitumor activity and the difficulty of conducting large controlled trials in multiple rare biomarker-defined populations. Further evidence will be needed to identify which tumor types derive the greatest benefit, which patients experience only brief disease control and whether earlier use can improve outcomes without creating excessive toxicity.
Why HER2 testing and pathology consistency may become the biggest adoption barrier
The regulatory decision may be broad, but practical access begins with a tissue sample and an accurate IHC result. HER2 testing is already embedded in breast and gastric cancer pathways, where pathology laboratories have established procedures, scoring systems and quality controls. Routine testing is less consistent in several of the additional cancers potentially covered by the tumor-agnostic indication.
The approval could encourage wider HER2 screening in biliary tract, bladder, cervical, endometrial, ovarian, pancreatic and other metastatic tumors. That would represent a meaningful diagnostic change because patients cannot be considered for treatment when HER2 status has never been evaluated. Multidisciplinary tumor boards may also need to revisit older pathology samples or request new biopsies when a patient reaches later treatment lines.
Testing expansion will not be straightforward. HER2 expression can vary within a tumor and between primary and metastatic sites, while specimen quality and previous treatment may affect the material available for assessment. Pathologists will need validated methods and clear interpretation standards for cancers in which HER2 scoring has historically been less common.
Another potential source of confusion is the difference between HER2 protein overexpression, HER2 gene amplification and activating HER2 mutations. These biomarkers can overlap, but they are not interchangeable. The new European indication is defined by IHC 3+ protein expression, while Enhertu also has a separate lung cancer indication linked to activating HER2 mutations.
Precision oncology increasingly depends on panels that detect genomic alterations, but a sequencing result alone may not establish eligibility for an indication based on strong protein expression. Laboratories and oncology teams will need workflows that connect genomic testing, immunohistochemistry and clinical history without treating every HER2-related result as equivalent.
The commercial reach of the approval will therefore depend partly on diagnostics rather than drug supply alone. Broader testing could enlarge the identifiable patient population, but inconsistent screening or reimbursement for pathology could leave eligible patients undiscovered. The regulatory label may be tumor agnostic, while healthcare infrastructure remains decidedly tumor specific.
What Enhertu adds to existing HER2 strategies and tumor-agnostic oncology
HER2-directed treatment is not new, but its use has historically been concentrated in selected breast and gastric cancers, with more recent expansion into lung and biliary tract settings. Trastuzumab-based regimens, pertuzumab, trastuzumab emtansine, HER2 tyrosine kinase inhibitors and newer antibodies have each established roles in particular diseases or treatment sequences.
Enhertu adds a different proposition by combining a HER2-targeting antibody with a topoisomerase I inhibitor payload. After binding to HER2 and entering the cancer cell, the conjugate releases its cytotoxic component. The payload can also affect nearby tumor cells, a characteristic that may help in cancers where HER2 expression is strong but not perfectly uniform.
The European decision also places an antibody drug conjugate within the growing class of tumor-agnostic therapies. Earlier biomarker-based approvals have largely involved immune checkpoint inhibitors for tumors with features such as microsatellite instability or high mutational burden, and selective inhibitors for uncommon genomic drivers such as NTRK fusions. Enhertu introduces strong HER2 protein expression as another cross-tumor treatment gateway.
This distinction has implications for drug development. Genomic biomarkers are often detected using sequencing, while HER2 eligibility in this indication depends on an IHC measurement of protein abundance. Future tumor-agnostic programmes may increasingly combine genomic, transcriptomic and protein-based selection rather than relying on one diagnostic technology.
The approval may also intensify competition among antibody drug conjugate developers. A platform that can produce activity across anatomically unrelated cancers potentially supports broader development than a programme built around one tumor type. However, the Enhertu experience also demonstrates that strong platform activity does not eliminate the need to understand cancer-specific response duration, resistance and safety.
Why safety management remains central as Enhertu enters less familiar tumor settings
Enhertu’s safety profile is well characterized from its established oncology uses, but expanding treatment into additional cancers will introduce the medicine to more clinicians, hospitals and patient populations. The most consequential known risk remains interstitial lung disease and pneumonitis, which can become severe or fatal if not recognized and managed promptly.
In the pooled safety analysis supporting the European indication, grade 5 adverse reactions occurred in 1.1% of patients, including fatal interstitial lung disease or pneumonitis in 1.0%. Other clinically important adverse reactions included neutropenia, anemia, fatigue, leukopenia, thrombocytopenia, nausea, gastrointestinal effects, pneumonia and decreased cardiac ejection fraction.
The absence of an unexpected new safety signal does not make these risks minor. Trial protocols generally involve defined monitoring, experienced investigators and eligibility criteria that may exclude patients with important pulmonary or cardiac conditions. Real-world populations can be more medically complex and may have received several previous treatments that affect bone marrow, lung or cardiac reserve.
The challenge will be particularly relevant at centers that have limited prior experience with trastuzumab deruxtecan. Treatment pathways require coordination among oncologists, nurses, radiologists and pulmonary specialists because respiratory symptoms can overlap with infection, cancer progression, pulmonary embolism or treatment-related lung injury. Delayed recognition may narrow the opportunity to interrupt therapy and manage toxicity.
Safety may also influence treatment sequencing. A response rate near 50% can be compelling in a population with few alternatives, but the risk-benefit balance may look different when another active treatment remains available. Clinicians will need to weigh expected response durability, prior pulmonary history, cumulative toxicity and the biology of the individual tumor rather than treating the pan-tumor label as an automatic choice.
How reimbursement and national rollout could produce an uneven European launch
European Commission approval permits marketing across the European Union, but it does not guarantee immediate or uniform access. Pricing negotiations, health technology assessments and national reimbursement decisions will shape when and where the new indication enters routine clinical practice.
Assessment bodies may examine the absence of randomized comparative evidence, the diversity of tumor types and the small number of patients in some subgroups. The rarity of eligible IHC 3+ populations can support an unmet-need argument, but it also makes conventional cost-effectiveness modelling more uncertain. Response duration differences between the pan-tumor, lung and colorectal datasets may further complicate attempts to apply one economic assumption across all cancers.
Budget impact will involve more than the medicine itself. Wider adoption may require additional pathology testing, repeat biopsies, infusion capacity, imaging and toxicity monitoring. Hospitals may need to identify which departments are responsible for testing and treatment when eligible patients are distributed across several oncology specialties.
Access could therefore develop at different speeds across Europe. Countries with established molecular tumor boards and broad reimbursement for biomarker testing may integrate the indication relatively quickly. Systems with restrictive testing criteria or lengthy indication-specific reviews could experience a substantial gap between regulatory approval and routine availability.
What clinicians, regulators and ADC developers will be watching next
The next phase will test whether the response rates observed in clinical trials translate into durable real-world benefit across diverse healthcare systems. Registries and post-authorisation studies can clarify treatment duration, discontinuation patterns, pulmonary toxicity and outcomes in patients who would not have met the original trial criteria.
More granular tumor-specific results will also be important. A broad approval can solve the regulatory problem of very small patient populations, but oncologists still need disease-specific information when selecting among competing therapies. Evidence on progression-free survival, overall survival, resistance mechanisms and sequencing will determine whether Enhertu becomes a routine late-line option or remains concentrated in selected cancers.
Testing patterns will provide another early signal. A meaningful increase in HER2 IHC testing across nontraditional tumor types would show that the approval is changing diagnostic behaviour, even before drug utilisation rises substantially. Limited testing expansion would suggest that the treatment opportunity is being constrained by infrastructure rather than clinical demand.
For the antibody drug conjugate sector, the approval validates the possibility of developing a targeted conjugate across multiple cancers using a shared biomarker. It also raises the evidence standard for competitors, which will need to show not only broad response activity but convincing durability, manageable toxicity and reliable patient selection.
Enhertu’s European tumor-agnostic approval is therefore a significant precision oncology milestone, but it is not the end of the development story. Its true impact will be determined by how consistently Europe identifies IHC 3+ tumors, how carefully toxicity is managed and whether subsequent evidence confirms durable benefit within each cancer population.
Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →